Cancer Genetics Registers Shares Underlying Existing Warrants; No Change in Fully Diluted Share Count
December 22, 2016 17:40 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics
December 07, 2016 07:53 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular...
Cancer Genetics, Inc. Listed by Merck as a National Reference Laboratory for KEYTRUDA® (pembrolizumab) Companion Diagnostic Testing
December 05, 2016 08:14 ET
|
Cancer Genetics, Inc.
Reinforces CGI’s Position as a Leader in Immuno-Oncology & Companion Diagnostics For PD-L1 Testing & MonitoringCompany Expects Significant Growth in Comprehensive Molecular & Immune...
Cancer Genetics, Inc. and Leading Collaborators to Present Innovative Insights That Will Advance Precision Medicine in Diffuse Large B-cell Lymphoma (DLBCL) at American Society of Hematology (ASH) Annual Meeting 2016
December 01, 2016 09:20 ET
|
Cancer Genetics, Inc.
The two studies presented at ASH highlight new data on genomic and immune biomarkers, as well as biological pathways of the aggressive cancer diffuse large B-cell lymphoma (DLBCL), the most common...
Cancer Genetics, Inc. Ranked Among Fastest Growing Companies For Third Consecutive Year By Deloitte’s Technology Fast 500™ - Ranks 233 in 2016
November 16, 2016 16:01 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology through the use of molecular markers and...
Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year Revenue Growth and Highlights Path to Future Profitability
November 10, 2016 07:00 ET
|
Cancer Genetics, Inc.
Company reports third quarter revenues of $6.8 Million, an increase of 68% over the third quarter of 2015The revenue growth rate was 58% for the first 9 months of 2016 as compared to...
Cancer Genetics, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016
November 03, 2016 07:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics, Inc. Launches Focus::Renal™, a Unique, Comprehensive and Highly Sensitive Next Generation Sequencing (NGS) Panel for Enabling Precision and Personalized Medicine in Renal Cancers
November 02, 2016 07:00 ET
|
Cancer Genetics, Inc.
Cancer Genetics, Inc. received CLIA approval for Focus::Renal™, a unique, highly sensitive and comprehensive NGS panel for renal cancer. Focus::Renal™ was developed as a result of multiple...
Cancer Genetics, Inc. to Present Insights on Patient Stratification & Diagnostics for Immunotherapy Trials at the Companion Diagnostics (CDx) Symposium on November 2-3
November 01, 2016 07:00 ET
|
Cancer Genetics, Inc.
The CDx market is expected to reach six billion US dollars by 2022 and drive significant cost savings by improving trial outcomes and enabling precision patient segmentation strategies.CGI will be...
Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock Conference on October 20
October 14, 2016 16:01 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...